128 related articles for article (PubMed ID: 38386285)
1. Biodistribution of Radioactively Labeled Splice Modulating Antisense Oligonucleotides After Intracerebroventricular and Intrathecal Injection in Mice.
Metz T; Welling MM; Suidgeest E; Nieuwenhuize E; de Vlaam T; Curtis D; Hailu TT; van der Weerd L; van Roon-Mom WMC
Nucleic Acid Ther; 2024 Feb; 34(1):26-34. PubMed ID: 38386285
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of SPECT-CT Imaging to Study the Pharmacokinetics of Antisense Oligonucleotides in a Mouse Model of Duchenne Muscular Dystrophy.
van de Steeg E; Läppchen T; Aguilera B; Jansen HT; Muilwijk D; Vermue R; van der Hoorn JW; Donato K; Rossin R; de Visser PC; Vlaming MLH
Nucleic Acid Ther; 2017 Aug; 27(4):221-231. PubMed ID: 28418733
[TBL] [Abstract][Full Text] [Related]
3. Distribution and Penetration of Intracerebroventricularly Administered 2'OMePS Oligonucleotide in the Mouse Brain.
Casaca-Carreira J; Temel Y; Larrakoetxea I; Jahanshahi A
Nucleic Acid Ther; 2017 Feb; 27(1):4-10. PubMed ID: 27753537
[TBL] [Abstract][Full Text] [Related]
4. Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy.
van Deutekom J; Beekman C; Bijl S; Bosgra S; van den Eijnde R; Franken D; Groenendaal B; Harquouli B; Janson A; Koevoets P; Mulder M; Muilwijk D; Peterburgska G; Querido B; Testerink J; Verheul R; de Visser P; Weij R; Aartsma-Rus A; Puoliväli J; Bragge T; O'Neill C; Datson NA
Nucleic Acid Ther; 2023 Jun; 33(3):193-208. PubMed ID: 37036788
[TBL] [Abstract][Full Text] [Related]
5. Convective forces increase rostral delivery of intrathecal radiotracers and antisense oligonucleotides in the cynomolgus monkey nervous system.
Sullivan JM; Mazur C; Wolf DA; Horky L; Currier N; Fitzsimmons B; Hesterman J; Pauplis R; Haller S; Powers B; Tayefeh L; DeBrosse-Serra B; Hoppin J; Kordasiewicz H; Swayze EE; Verma A
J Transl Med; 2020 Aug; 18(1):309. PubMed ID: 32771027
[TBL] [Abstract][Full Text] [Related]
6. Exonic sequences provide better targets for antisense oligonucleotides than splice site sequences in the modulation of Duchenne muscular dystrophy splicing.
Aartsma-Rus A; Houlleberghs H; van Deutekom JC; van Ommen GJ; 't Hoen PA
Oligonucleotides; 2010 Apr; 20(2):69-77. PubMed ID: 20377429
[TBL] [Abstract][Full Text] [Related]
7. Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms.
Aartsma-Rus A; van Vliet L; Hirschi M; Janson AA; Heemskerk H; de Winter CL; de Kimpe S; van Deutekom JC; 't Hoen PA; van Ommen GJ
Mol Ther; 2009 Mar; 17(3):548-53. PubMed ID: 18813282
[TBL] [Abstract][Full Text] [Related]
8. Investigating the Impact of Delivery Routes for Exon Skipping Therapies in the CNS of DMD Mouse Models.
Saoudi A; Fergus C; Gileadi T; Montanaro F; Morgan JE; Kelly VP; Tensorer T; Garcia L; Vaillend C; Muntoni F; Goyenvalle A
Cells; 2023 Mar; 12(6):. PubMed ID: 36980249
[TBL] [Abstract][Full Text] [Related]
9. Delivery of antisense oligonucleotides for splice-correction of androgen receptor pre-mRNA in castration-resistant prostate cancer models using cell-penetrating peptides.
Luna Velez MV; Paulino da Silva Filho O; Verhaegh GW; van Hooij O; El Boujnouni N; Brock R; Schalken JA
Prostate; 2022 May; 82(6):657-665. PubMed ID: 35098567
[TBL] [Abstract][Full Text] [Related]
10. The Use of Antisense Oligonucleotides for the Treatment of Duchenne Muscular Dystrophy.
Relizani K; Goyenvalle A
Methods Mol Biol; 2018; 1687():171-183. PubMed ID: 29067663
[TBL] [Abstract][Full Text] [Related]
11. Delivery of Antisense Oligonucleotides to the Mouse Brain by Intracerebroventricular Injections.
Metz T; Kuijper EC; van Roon-Mom WMC
Methods Mol Biol; 2022; 2434():333-341. PubMed ID: 35213029
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts.
Maruyama R; Touznik A; Yokota T
J Vis Exp; 2018 May; (135):. PubMed ID: 29806836
[TBL] [Abstract][Full Text] [Related]
13. Trafficking of intracerebroventricularly injected antisense oligonucleotides in the mouse brain.
Chauhan NB
Antisense Nucleic Acid Drug Dev; 2002 Oct; 12(5):353-7. PubMed ID: 12477284
[TBL] [Abstract][Full Text] [Related]
14. Dose-dependent pharmacokinetic profiles of 2'-O-methyl phosphorothioate antisense oligonucleotidesin mdx mice.
Verhaart IE; Tanganyika-de Winter CL; Karnaoukh TG; Kolfschoten IG; de Kimpe SJ; van Deutekom JC; Aartsma-Rus A
Nucleic Acid Ther; 2013 Jun; 23(3):228-37. PubMed ID: 23634945
[TBL] [Abstract][Full Text] [Related]
15. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
16. Antisense Oligonucleotide Design and Evaluation of Splice-Modulating Properties Using Cell-Based Assays.
Slijkerman R; Kremer H; van Wijk E
Methods Mol Biol; 2018; 1828():519-530. PubMed ID: 30171565
[TBL] [Abstract][Full Text] [Related]
17. Direct Administration and Gene Modulation Using Antisense Oligonucleotides Within the CNS.
Wahlestedt C; Khorkova O
Cell Mol Neurobiol; 2021 Jul; 41(5):849-853. PubMed ID: 32656646
[TBL] [Abstract][Full Text] [Related]
18. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.
Heemskerk HA; de Winter CL; de Kimpe SJ; van Kuik-Romeijn P; Heuvelmans N; Platenburg GJ; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
J Gene Med; 2009 Mar; 11(3):257-66. PubMed ID: 19140108
[TBL] [Abstract][Full Text] [Related]
19. Lowering Mutant Huntingtin Using Tricyclo-DNA Antisense Oligonucleotides As a Therapeutic Approach for Huntington's Disease.
Imbert M; Blandel F; Leumann C; Garcia L; Goyenvalle A
Nucleic Acid Ther; 2019 Oct; 29(5):256-265. PubMed ID: 31184975
[TBL] [Abstract][Full Text] [Related]
20. Overview on AON design.
Aartsma-Rus A
Methods Mol Biol; 2012; 867():117-29. PubMed ID: 22454058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
